Funder
Foundation for the National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference33 articles.
1. Ao L et al (2012) Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib. Mol Pharm 9:2197–2205.
https://doi.org/10.1021/mp300044b
2. Baker AF, Hanke NT, Sands BJ, Carbajal L, Anderl JL, Garland LL (2014) Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models. J Exp Clin Can Res CR 33:111.
https://doi.org/10.1186/s13046-014-0111-8
3. Bielcikova Z, Jakabova A, Pinkas M, Zemanova M, Kolostova K, Bobek V (2017) Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics? Am J Transl Res 9:2807–2823
4. Chauhan D et al (2007) A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma Oncogene 26:2374–2380.
https://doi.org/10.1038/sj.onc.1210028
5. Eckford PD, Sharom FJ (2009) ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 109:2989–3011.
https://doi.org/10.1021/cr9000226